All News

This week, the top managed care news included the 2020 budget plan proposing a mix of healthcare spending cuts and increases; the FDA approving the first immunotherapy regimen for breast cancer; and researchers uncovering how sodium glucose co-transporter-2 inhibitors work.

The industry is speedily moving and advancing, and the only way for hospitals see continued success is if they stay nimble and capable of adapting to new developments. Looking to the future, healthcare systems should concern themselves less with size and instead shift focus to adopting business and payment models that bring value.

The European Headache Federation (EHF) recently sought to create an expert- and evidence-based guideline for the treatment of migraine with monoclonal antibodies that target the calcitonin gene-related peptide (CGRP). However, in reviewing available research, the EHF found that there was not enough evidence to provide a guideline based on the Grading of Recommendation, Assessment, Development, and Evaluation approach.

In an effort to increase patient accrual, broaden patients’ access to cancer clinical trials, and lead to trial results that better represent treatment effects in the real world, the FDA published 4 draft guidances and 1 final guidance to promote the inclusion of pediatric patients and patients with comorbidities that can occur alongside cancer.

The president has released his budget for fiscal year (FY) 2020, which calls for converting Medicaid to a system of block grants and requiring all able-bodied Medicaid recipients to hold a job or perform community service. The $87.1 billion allocated to HHS, a 12% cut, would include increases to federal HIV funding, but drops in global funding, as well as cuts to the National Institutes of Health (NIH).

A longitudinal 5-year observational study to examine functional and structural cerebral changes in adult-onset myotonic dystrophies found some differences between the 2 types of this incurable genetic disorder and said that additional brain studies are needed in light of upcoming treatment trials for this rare disease.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text